India's pharmaceutical market charged into 2026 with strong momentum, posting 11% YoY value growth to ₹20,836 crore in February, according to Pharmarack's PharmaTrac Acquaint report. The moving annual total (MAT) reached ₹2.44 lakh crore, up 8.4%, propelled by price hikes (5.3%), new launches (3.5%), and volume gains (2.2%).[1][2][3]
Therapy Leaders and Anti-Diabetic Dominance
Cardiac held the top spot at 14.8% growth (₹2,937 crore), trailed by anti-diabetics surging 15.5% to ₹1,982 crore (9.5% IPM share) and vit/min/nutr at 13.3% (₹1,831 crore). Anti-diabetics shone via 13% new product acceleration, especially GLP-1 agonists like tirzepatide. Leading companies: Abbott (1st, outperformed therapy), USV (2nd), Sun Pharma (3rd, outperformed), Lupin (4th), Eli Lilly (5th).[2][1]
Free Membership Required
You must be a Free member to access this content.
